Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis

Table 3 Summary of nintedanib-related toxicities

	CTC grade, n (%)
Patients with drug-related AEs, n (%)	1	2	3	4	Total
Total	18 (60)	6 (20)	2 (7)	1 (3)	27 (90)
Gastrointestinal disorders	16 (53)	7 (23)	0	0	23 (77)
Nausea	16 (53)	4 (13)	0	0	20 (67)
Vomiting	14 (47)	2 (7)	0	0	16 (53)
Diarrhoea	7 (23)	5 (17)	0	0	12 (40)
Investigations	2 (7)	1 (3)	2 (7)	1 (3)	6 (20)
Hepatic enzyme increased	0	1 (3)	0	1 (3)	2 (7)
ALT increased	0	1 (3)	0	0	1 (3)
AST increased	0	1 (3)	1 (3)	0	2 (7)
GGT increased	0	1 (3)	0	0	1 (3)
CD4 decreased	0	0	2 (7)	0	2 (7)
General disorders	5 (17)	0	0	0	5 (17)
Fatigue	5 (17)	0	0	0	5 (17)

Abbreviations: AE adverse event, ALT alanine aminotransferase, AST aspartate aminotransferase, CTC Common Toxicity Criteria, GGT gamma-glutamyl transpeptidase.